During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for ...

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for ...

A multicenter study evaluating lurbinectedin in patients with extensive-stage small cell lung cancer who received second-line ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

Panelists discuss how implementing combination immunotherapy in clinical practice faces institutional barriers, including ...